Maribavir tablets for CMV infection after transplant

This study looks at how well the drug maribavir works in adults with kidney failure who get a CMV infection after a transplant. It focuses on people whose CMV infection hasn't responded to other treatments.

This Phase 3 trial tests maribavir (an anti-CMV medicine) in children and teens who get CMV infection after a stem cell or solid organ transplant. It aims to see whether the drug is safe and well-tolerated, and whether it can reduce the virus in the body.

This study tests a new medicine called maribavir for Chinese adults who have a CMV infection that hasn't gotten better with standard treatments. It may be an option for transplant recipients who need a different approach.

This study tests a medication called LIVTENCITY (maribavir) for adults in South Korea who have a CMV infection after a transplant. It is for people whose infection has not improved or has become resistant to other antiviral medicines.

This trial tests a new drug, maribavir, for controlling or treating active CMV infection in people with certain blood cancers (multiple myeloma, follicular lymphoma, or large B-cell lymphoma) who are taking a bispecific antibody therapy. The goal is to see if maribavir is safe and effective for managing CMV in this specific situation.

This study tests a medicine called maribavir for people who have a CMV infection after a stem cell transplant. It watches how well the medicine works and how safe it is.